` FBRX (Forte Biosciences Inc) vs S&P 500 Comparison - Alpha Spread

FBRX
vs
S&P 500

Over the past 12 months, FBRX has outperformed S&P 500, delivering a return of +21% compared to the S&P 500's +17% growth.

Stocks Performance
FBRX vs S&P 500

Loading
FBRX
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
FBRX vs S&P 500

Performance Gap Between FBRX and GSPC
HIDDEN
Show

Performance By Year
FBRX vs S&P 500

Loading
FBRX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Forte Biosciences Inc vs Peers

S&P 500
FBRX
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Forte Biosciences Inc
Glance View

Market Cap
293.8m USD
Industry
Biotechnology

Forte Biosciences, Inc. is a clinical stage biopharmaceutical company focused on dermatology. The company is headquartered in Torrance, California and currently employs 5 full-time employees. The company went IPO on 2017-04-13. The firm is focused on its lead product candidate, FB-401, which is a topical live biotherapeutic for the treatment of inflammatory skin diseases, including pediatric and adult patients with atopic dermatitis (AD). FB401 was developed in collaboration with the National Institutes of Health (NIH), and the National Institute of Allergy and Infectious Diseases (NIAID). FB-401 has completed Phase I/II a testing in adult and pediatric patients with atopic dermatitis.

FBRX Intrinsic Value
Not Available
Back to Top